» Articles » PMID: 27113466

International Field Testing of the Psychometric Properties of an EORTC Quality of Life Module for Oral Health: the EORTC QLQ-OH15

Abstract

Purpose: This international EORTC validation study (phase IV) is aimed at testing the psychometric properties of a quality of life (QoL) module related to oral health problems in cancer patients.

Methods: The phase III module comprised 17 items with four hypothesized multi-item scales and three single items. In phase IV, patients with mixed cancers, in different treatment phases from 10 countries completed the EORTC QLQ-C30, the QLQ-OH module, and a debriefing interview. The hypothesized structure was tested using combinations of classical test theory and item response theory, following EORTC guidelines. Test-retest assessments and responsiveness to change analysis (RCA) were performed after 2 weeks.

Results: Five hundred seventy-two patients (median age 60.3, 54 % females) were analyzed. Completion took <10 min for 84 %, 40 % expressed satisfaction that these issues were addressed. Analyses suggested a revision of the phase III hypothesized scale structure. Two items were deleted based on a high degree of item misfit, together with negative patient feedback. The remaining 15 items formed one eight-item scale named OH-QoL score, a two-item information scale, a two-item scale regarding dentures, and three single items (sticky saliva/mouth soreness/sensitivity to food/drink). Face and convergent validity and internal consistency were confirmed. Test-retest reliability (n = 60) was demonstrated as was RCA for patients undergoing chemotherapy (n = 117; p = 0.06). The resulting QLQ-OH15 discriminated between clinically distinct patient groups, e.g., low performance status vs. higher (p < 000.1), and head-and-neck cancer versus other cancers (p < 0.03).

Conclusion: The EORTC module QLQ-OH15 is a short, well-accepted assessment tool focusing on oral problems and QoL to improve clinical management.

Trial Registration: ClinicalTrials.gov Identifier: NCT01724333.

Citing Articles

Cross-Cultural Adaptation and Validation of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Oral Health 15 into Hindi Version for Cancer Patients.

Agrawal N, Gupta N, Siddiqui S Indian J Palliat Care. 2025; 31(1):52-59.

PMID: 40027978 PMC: 11866660. DOI: 10.25259/IJPC_242_2024.


Salivary flow rate, subjective oral dryness and dental caries 5 years after haematopoietic cell transplantation.

Bulthuis M, van Gennip L, Thomas R, van Leeuwen S, Bronkhorst E, Laheij A BMC Oral Health. 2024; 24(1):1058.

PMID: 39256697 PMC: 11389434. DOI: 10.1186/s12903-024-04804-7.


Self-perceived oral health in hemato-oncological patients and the relation to quality of life.

Laheij A, Dillen L, Nur E, Raber-Durlacher J Support Care Cancer. 2024; 32(10):643.

PMID: 39243322 PMC: 11380634. DOI: 10.1007/s00520-024-08849-w.


Exploring the integration of dentistry within a multidisciplinary palliative care team: does bedside dental care improve quality of life and symptom burden in inpatient palliative care patients?.

Uhlig S, Doberschutz F, Hallmann F, Salm H, Sigle J, Pink D Support Care Cancer. 2024; 32(8):491.

PMID: 38976073 PMC: 11231016. DOI: 10.1007/s00520-024-08671-4.


Evaluating conceptual model measurement and psychometric properties of Oral health-related quality of life instruments available for older adults: a systematic review.

Deana N, Pardo Y, Ferrer M, Espinoza-Espinoza G, Garin O, Munoz-Millan P Health Qual Life Outcomes. 2024; 22(1):5.

PMID: 38218930 PMC: 10787424. DOI: 10.1186/s12955-023-02218-7.


References
1.
Elad S, Epstein J, Raber-Durlacher J, Donnelly P, Strahilevitz J . The antimicrobial effect of Iseganan HCl oral solution in patients receiving stomatotoxic chemotherapy: analysis from a multicenter, double-blind, placebo-controlled, randomized, phase III clinical trial. J Oral Pathol Med. 2011; 41(3):229-34. DOI: 10.1111/j.1600-0714.2011.01094.x. View

2.
Lalla R, Bowen J, Barasch A, Elting L, Epstein J, Keefe D . MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014; 120(10):1453-61. PMC: 4164022. DOI: 10.1002/cncr.28592. View

3.
Bjordal K, Ahlner-Elmqvist M, Tollesson E, Jensen A, Razavi D, Maher E . Development of a European Organization for Research and Treatment of Cancer (EORTC) questionnaire module to be used in quality of life assessments in head and neck cancer patients. EORTC Quality of Life Study Group. Acta Oncol. 1994; 33(8):879-85. DOI: 10.3109/02841869409098450. View

4.
Sodergren S, White A, Efficace F, Sprangers M, Fitzsimmons D, Bottomley A . Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the EORTC Quality of Life Group. Crit Rev Oncol Hematol. 2014; 91(1):35-46. DOI: 10.1016/j.critrevonc.2014.01.002. View

5.
Vivat B, Young T, Efficace F, Sigurdadottir V, Arraras J, Asgeirsdottir G . Cross-cultural development of the EORTC QLQ-SWB36: a stand-alone measure of spiritual wellbeing for palliative care patients with cancer. Palliat Med. 2012; 27(5):457-69. DOI: 10.1177/0269216312451950. View